Causal Relationship between Ischemic Stroke and Malignant Brain Tumors: A Two-Sample Mendelian Randomization Analysis
DOI:
https://doi.org/10.54097/jannsp45Keywords:
Strokes, Malignant Cerebral Neoplasms, Mendelian RandomizationAbstract
Object: Contemporary observational research has identified associations between cerebrovascular accidents, commonly referred to as strokes, and malignant cerebral neoplasms. However, these studies fall short of elucidating the presence of a direct causal relationship between the two conditions. In our investigation, we employ aggregated data derived from large-scale population-based genome-wide association studies (GWASs), to interrogate the potential causal linkages between these two pathologies. Method: This investigation leverages the two-sample Mendelian randomization (MR) methodology to elucidate the genetic underpinnings of the causal nexus between malignant cerebral neoplasms and ischemic cerebrovascular accidents. Rigorous quality control protocols were enacted to identify SNPs that exhibit a robust association with the exposure variable, namely malignant brain tumors. Analytical strategies, including MR-Egger regression, weighted median, inverse-variance weighted (IVW), simple mode, and weight mode methods, constituted the core of our MR analytical framework. Predominantly, the findings hinge upon the IVW method. To fortify the veracity of our conclusions, an array of sensitivity analyses such as MR-Egger regression, weighted median, MR pleiotropy, MR-PRESSO and radial MR, were deployed to meticulously evaluate heterogeneity and pleiotropy. Result: The findings derived from the IVW model reveal an absence of a significant causal nexus between malignant cerebral neoplasms and any categorization of cerebrovascular accidents, encompassing any strokes (AS) (OR 0.998, 95% CI 0.99-1.01, P=0.741), any ischemic strokes (AIS) (OR 0.999, 95% CI 0.99-1.01, P=0.999), large artery strokes (LAS) (OR 0.993, 95% CI 0.97-1.02, P=0.603), cardioembolic strokes (CES) (OR 1.012, 95% CI 0.99-1.03, P=0.275), and small vessel strokes (SVS) (OR 0.998, 95% CI 0.98-1.02, P=0.880) with respect to either an escalation or reduction in risk. Additionally, the analyses did not unveil any indications of heterogeneity or horizontal pleiotropy within the dataset. On a genome-wide scale, none of the variants associated with malignant brain tumors demonstrated relevance to the investigated outcomes. Conclusion: The outcomes of this MR investigation reveal the absence of a causal linkage between malignant cerebral neoplasms and ischemic cerebrovascular accidents. Nonetheless, the observed correlation between these two pathologies warrants attention, underscoring the necessity for heightened surveillance and care for individuals concurrently afflicted with both conditions.
Downloads
References
[1] Reifenberger G, Wirsching H-G, Knobbe-Thomsen C B, et al. Advances in the molecular genetics of gliomas - implications for classification and therapy [J]. Nat Rev Clin Oncol, 2017, 14(7): 434-52.
[2] Sanai N, Alvarez-Buylla A, Berger M S. Neural stem cells and the origin of gliomas [J]. N Engl J Med, 2005, 353(8): 811-22.
[3] Weller M, Wick W, Aldape K, et al. Glioma [J]. Nat Rev Dis Primers, 2015, 1: 15017.
[4] Wang L M, Englander Z K, Miller M L, et al. Malignant Glioma [J]. Adv Exp Med Biol, 2023, 1405.
[5] Bao Z, Wang Y, Wang Q, et al. Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution [J]. Front Med, 2021, 15(4): 551-61.
[6] Morshed R A, Young J S, Kroliczek A A, et al. A Neurosurgeon's Guide to Cognitive Dysfunction in Adult Glioma [J]. Neurosurgery, 2021, 89(1).
[7] Lathia J D, Mack S C, Mulkearns-Hubert E E, et al. Cancer stem cells in glioblastoma [J]. Genes Dev, 2015, 29(12): 1203-17.
[8] Sanossian N, Djabiras C, Mack W J, et al. Trends in cancer diagnoses among inpatients hospitalized with stroke [J]. J Stroke Cerebrovasc Dis, 2013, 22(7): 1146-50.
[9] Tu W-J, Zhao Z, Yin P, et al. Estimated Burden of Stroke in China in 2020 [J]. JAMA Netw Open, 2023, 6(3): e231455.
[10] Saini V, Guada L, Yavagal D R. Global Epidemiology of Stroke and Access to Acute Ischemic Stroke Interventions [J]. Neurology, 2021, 97(20 Suppl 2).
[11] Wu S, Wu B, Liu M, et al. Stroke in China: advances and challenges in epidemiology, prevention, and management [J]. Lancet Neurol, 2019, 18(4): 394-405.
[12] Hu Y, Haessler J W, Manansala R, et al. Whole-Genome Sequencing Association Analyses of Stroke and Its Subtypes in Ancestrally Diverse Populations From Trans-Omics for Precision Medicine Project [J]. Stroke, 2022, 53(3): 875-85.
[13] Danaei G, Finucane M M, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants [J]. Lancet, 2011, 378(9785): 31-40.
[14] Feigin V L, Roth G A, Naghavi M, et al. Global burden of stroke and risk factors in 188 countries, during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 [J]. Lancet Neurol, 2016, 15(9): 913-24.
[15] Finucane M M, Stevens G A, Cowan M J, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants [J]. Lancet, 2011, 377(9765): 557-67.
[16] Ma Q, Li R, Wang L, et al. Temporal trend and attributable risk factors of stroke burden in China, 1990-2019: an analysis for the Global Burden of Disease Study 2019 [J]. Lancet Public Health, 2021, 6(12): e897-e906.
[17] Salazar-Camelo R A, Moreno-Vargas E A, Cardona A F, et al. Ischemic stroke: A paradoxical manifestation of cancer [J]. Crit Rev Oncol Hematol, 2021, 157: 103181.
[18] Becattini C, Giustozzi M, Portillo J, et al. Acute venous thromboembolism in patients with brain cancer: clinical course [J]. Res Pract Thromb Haemost, 2023, 7(6): 102172.
[19] Clouston P D, DeAngelis L M, Posner J B. The spectrum of neurological disease in patients with systemic cancer [J]. Ann Neurol, 1992, 31(3): 268-73.
[20] Tan J-S, Ren J-M, Fan L, et al. Genetic Predisposition of Anti-Cytomegalovirus Immunoglobulin G Levels and the Risk of 9 Cardiovascular Diseases [J]. Front Cell Infect Microbiol, 2022, 12: 884298.
[21] Tan J-S, Liu N-N, Guo T-T, et al. Genetically predicted obesity and risk of deep vein thrombosis [J]. Thromb Res, 2021, 207: 16-24.
[22] Tan J-S, Liu N-N, Guo T-T, et al. Genetic predisposition to COVID-19 may increase the risk of hypertension disorders in pregnancy: A two-sample Mendelian randomization study [J]. Pregnancy Hypertens, 2021, 26: 17-23.
[23] Tan J-S, Hu M-J, Yang Y-M, et al. Genetic Predisposition to Low-Density Lipoprotein Cholesterol May Increase Risks of Both Individual and Familial Alzheimer's Disease [J]. Front Med (Lausanne), 2021, 8: 798334.
[24] Ma J, Li J, Jin C, et al. Association of gut microbiome and primary liver cancer: A two-sample Mendelian randomization and case-control study [J]. Liver Int, 2023, 43(1): 221-33.
[25] Davies N M, Holmes M V, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians [J]. BMJ, 2018, 362: k601.
[26] Adams H P, Bendixen B H, Kappelle L J, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment [J]. Stroke, 1993, 24(1): 35-41.
[27] Jiang L, Zheng Z, Fang H, et al. A generalized linear mixed model association tool for biobank-scale data [J]. Nat Genet, 2021, 53(11): 1616-21.
[28] Malik R, Chauhan G, Traylor M, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes [J]. Nat Genet, 2018, 50(4): 524-37.
[29] Emdin C A, Khera A V, Kathiresan S. Mendelian Randomization [J]. JAMA, 2017, 318(19): 1925-6.
[30] Bowden J, Del Greco M F, Minelli C, et al. Improving the accuracy of two-sample summary-data Mendelian randomization: moving beyond the NOME assumption [J]. Int J Epidemiol, 2019, 48(3): 728-42.
[31] Bowden J, Spiller W, Del Greco M F, et al. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression [J]. Int J Epidemiol, 2018, 47(4): 1264-78.
[32] Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression [J]. Int J Epidemiol, 2015, 44(2): 512-25.
[33] Bowden J, Davey Smith G, Haycock P C, et al. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator [J]. Genet Epidemiol, 2016, 40(4): 304-14.
[34] Slob E A W, Burgess S. A comparison of robust Mendelian randomization methods using summary data [J]. Genet Epidemiol, 2020, 44(4): 313-29.
[35] Li C, Niu M, Guo Z, et al. A Mild Causal Relationship Between Tea Consumption and Obesity in General Population: A Two-Sample Mendelian Randomization Study [J]. Front Genet, 2022, 13: 795049.
[36] Hartwig F P, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption [J]. Int J Epidemiol, 2017, 46(6): 1985-98.
[37] Burgess S, Butterworth A, Thompson S G. Mendelian randomization analysis with multiple genetic variants using summarized data [J]. Genet Epidemiol, 2013, 37(7): 658-65.
[38] Burgess S, Davey Smith G, Davies N M, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023 [J]. Wellcome Open Res, 2019, 4: 186.
[39] Verbanck M, Chen C-Y, Neale B, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases [J]. Nat Genet, 2018, 50(5): 693-8.
[40] Burgess S, Bowden J, Fall T, et al. Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants [J]. Epidemiology, 2017, 28(1): 30-42.
[41] Greco M F D, Minelli C, Sheehan N A, et al. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome [J]. Stat Med, 2015, 34(21): 2926-40.
[42] Brion M-J A, Shakhbazov K, Visscher P M. Calculating statistical power in Mendelian randomization studies [J]. Int J Epidemiol, 2013, 42(5): 1497-501.
[43] Zuber M. Stroke and cancer [J]. Rev Neurol (Paris), 2023, 179(5): 417-24.
[44] Turner M, Murchie P, Derby S, et al. Is stroke incidence increased in survivors of adult cancers? A systematic review and meta-analysis [J]. J Cancer Surviv, 2022, 16(6): 1414-48.
[45] Al-Dalahmah O, Argenziano M G, Kannan A, et al. Re-convolving the compositional landscape of primary and recurrent glioblastoma reveals prognostic and targetable tissue states [J]. Nat Commun, 2023, 14(1): 2586.
[46] Zhang C, Wang L, Guo Y, et al. Systematic analysis of brain and skull ischemic injury expression profiles reveals associations of the tumor immune microenvironment and cell death with ischemic stroke [J]. Front Immunol, 2022, 13: 1082546.
[47] Komlodi-Pasztor E, Gilbert M R, Armstrong T S. Diagnosis and Management of Stroke in Adults with Primary Brain Tumor [J]. Curr Oncol Rep, 2022, 24(10): 1251-9.
[48] Bang O Y, Chung J-W, Lee M J, et al. Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms [J]. J Stroke, 2020, 22(1).
[49] Pan Y, Liu Y, Wei W, et al. Extracellular Vesicles as Delivery Shippers for Noncoding RNA-Based Modulation of Angiogenesis: Insights from Ischemic Stroke and Cancer [J]. Small, 2023, 19(17): e2205739.
[50] Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities [J]. Cell Mol Life Sci, 2020, 77(9): 1745-70.
[51] Zamorano J L. Specific risk of atrial fibrillation and stroke in oncology patients [J]. Eur Heart J, 2016, 37(36): 2747-8.
[52] Cestari D M, Weine D M, Panageas K S, et al. Stroke in patients with cancer: incidence and etiology [J]. Neurology, 2004, 62(11): 2025-30.
[53] Elmariah S, Doros G, Benavente O R, et al. Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis [J]. Circ Cardiovasc Interv, 2018, 11(1): e005795.
[54] Adams H P. Cancer and Cerebrovascular Disease [J]. Curr Neurol Neurosci Rep, 2019, 19(10): 73.
[55] Zaorsky N G, Zhang Y, Tchelebi L T, et al. Stroke among cancer patients [J]. Nat Commun, 2019, 10(1): 5172.
[56] Zhang Y Y, Chan D K Y, Cordato D, et al. Stroke risk factor, pattern and outcome in patients with cancer [J]. Acta Neurol Scand, 2006, 114(6): 378-83.
[57] Hill H A, Kleinbaum D G. Bias in Observational Studies [M]. Encyclopedia of Biostatistics. 2005.
[58] Adair L S. Methods appropriate for studying the relationship of breast-feeding to obesity [J]. J Nutr, 2009, 139(2): 408S-11S.
[59] Stanley F J, Byard R W. The association between the prone sleeping position and sudden infant death syndrome (SIDS): an editorial overview [J]. J Paediatr Child Health, 1991, 27(6): 325-8.
[60] Goldberg R J, Pastides H, Ellison R C, et al. Uses of the case-control and cohort epidemiological approaches in pediatric practice and research [J]. Pediatr Res, 1985, 19(8): 787-90.
[61] Navi B B, Iadecola C. Ischemic stroke in cancer patients: A review of an underappreciated pathology [J]. Ann Neurol, 2018, 83(5): 873-83.
[62] Lee M J, Chung J-W, Ahn M-J, et al. Hypercoagulability and Mortality of Patients with Stroke and Active Cancer: The OASIS-CANCER Study [J]. J Stroke, 2017, 19(1): 77-87.
[63] Parikh N S, Burch J E, Kamel H, et al. Recurrent Thromboembolic Events after Ischemic Stroke in Patients with Primary Brain Tumors [J]. J Stroke Cerebrovasc Dis, 2017, 26(10): 2396-403.
[64] Zhang Y Y, Cordato D, Shen Q, et al. Risk factor, pattern, etiology and outcome in ischemic stroke patients with cancer: a nested case-control study [J]. Cerebrovasc Dis, 2007, 23(2-3): 181-7.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
